CoinShares替代幣主動型ETF DIME 深 滬
等待開盤 02-20 09:30:00 美东时间
8.4601
-0.138
-1.61%
華盛通- 最 高8.4601
- 今 開8.42
- 成交量 864股
- 最 低 8.3951
- 昨 收 8.5983
- 總市值 126.90万
- 52周最高 28.10
- 市盈率 靜 --
- 換手率 0.58%
- 52周最低 8.07
- 委 比 50.00%
- 總股本 15.00万
- 歷史最高 28.10
- 量 比 0.87
- 振 幅 0.76%
- 歷史最低 8.07
- 每 手 1
- 風險率 4.31%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BRIEF-Nano Dimension Adopts Limited Duration Shareholder Rights Agreement
BRIEF-Nano Dimension Adopts Limited Duration Shareholder Rights Agreement Feb 2 (Reuters) - Nano Dimension Ltd 2N5By.F : NANO DIMENSION ADOPTS LIMITED DURATION SHAREHOLDER RIGHTS AGREEMENT Source text: ID:nGNX1dxsdz Further company coverage: [2N5By.F] (( Reuters.Briefs@thomsonreuters.com ;))
02-03 07:30
BRIEF-Evertec To Acquire Dimensa For R$950 Million
BRIEF-Evertec To Acquire Dimensa For R$950 Million Feb 2 (Reuters) - Evertec Inc EVTC.N : EVERTEC TO ACQUIRE DIMENSA FOR R$950 MILLION Source text: ID:nBwknrLGa Further company coverage: EVTC.N (( Reuters.Briefs@thomsonreuters.com ;))
02-03 05:35
Arrowhead Pharmaceuticals Launches Phase 1/2a Trial of Dual-Target RNAi Therapy for Mixed Hyperlipidemia
Arrowhead Pharmaceuticals Launches Phase 1/2a Trial of Dual-Target RNAi Therapy for Mixed Hyperlipidemia Arrowhead Pharmaceuticals Inc. has announced the initiation of a Phase 1/2a clinical trial for ARO-DIMER-PA, an investigational RNA interference (RNAi) therapeutic being developed for the treatme
01-28 01:02
BUZZ-Arrowhead rises as it begins trial of high-cholesterol disorder drug
BUZZ-Arrowhead rises as it begins trial of high-cholesterol disorder drug ** Shares of Arrowhead Pharmaceuticals rise 2% to $67.95 ** California-based drugmaker says it has begun testing its experimental drug ARO-DIMER-PA for mixed hyperlipidemia, a disorder marked by high levels of cholesterol and
01-27 23:12
BRIEF-Nano Dimension Announces Fourth Quarter 2025 Revenue Exceeding Guidance And Provides Business Updates
BRIEF-Nano Dimension Announces Fourth Quarter 2025 Revenue Exceeding Guidance And Provides Business Updates Jan 21 (Reuters) - Nano Dimension Ltd 2N5By.F : NANO DIMENSION ANNOUNCES FOURTH QUARTER 2025 REVENUE EXCEEDING GUIDANCE AND PROVIDES BUSINESS UPDATES NANO DIMENSION LTD - EXPECTS Q4 2025 REVEN
01-21 21:34
BRIEF-Schneider Electric Sees 'Very Good' Data Centre Demand Outside North America - CEO
Dec 11 (Reuters) - Schneider Electric SE SCHN.PA: CEO BLUM SAYS HE SEES VERY GOOD DATA CENTRE DEMAND OUTSIDE NORTH AMERICA - MEDIA CALL CEO: DEMAND NOT YET SAME MAGNITUDE AS IN US, BUT VERY ROBUST GRO...
2025-12-11 15:55
Arrowhead Pharmaceuticals Unveils Pipeline Progress and First Commercial Launch in Investor Presentation
Arrowhead Pharmaceuticals Inc. has released a corporate presentation highlighting its recent achievements and future plans. The company reported its first commercial launch in 2025 with REDEMPLO® (plo...
2025-12-08 10:05
BRIEF-Tonix, Mass General Partner on Phase 2 Trial of TNX-1500 to Prevent Kidney Transplant Organ Rejection
Nov 4 (Reuters) - Tonix Pharmaceuticals Holding Corp TNXP.O: TONIX PHARMACEUTICALS ANNOUNCES COLLABORATION WITH MASSACHUSETTS GENERAL HOSPITAL TO ADVANCE PHASE 2 CLINICAL TRIAL OF DIMERIC FC-MODIFIED ...
2025-11-04 20:31
BRIEF-Nano Dimension Appoints John Brenton As CFO
Oct 21 (Reuters) - Nano Dimension Ltd 2N5By.F: NANO DIMENSION ANNOUNCES CHIEF FINANCIAL OFFICER TRANSITION NANO DIMENSION LTD - CFO ASSAF ZIPORI TO TRANSITION FROM ROLE NANO DIMENSION LTD - JOHN BRENT...
2025-10-22 05:21
CoinShares Makes Altcoin Investing Simple With Its New DIME ETF
CoinShares International Ltd. has launched the CoinShares Altcoins ETF (NASDAQ:DIME), a new fund that enables investors to access the red-hot altcoin market without the hassle of dealing with crypto wallets.
2025-10-08 00:52
